News and Analysis

Inflammatix snags $32 mln Series C

Burlingame, California-based Inflammatix, a molecular diagnostics company, has secured $32 million in Series C financing.

-

Burlingame, California-based Inflammatix, a molecular diagnostics company, has secured $32 million in Series C financing. The investors included Khosla Ventures, Northpond Ventures and Think.Health Ventures and Grey Sky Venture Partners.

Source: Press Release